Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Neoplasms, Hormone-Dependent 2Carcinoma, Lobular 2Carcinoma, Ductal, Breast 2Breast Neoplasms 2

Interventions

Letrozole 5Paclitaxel 4atamestane 3Toremifene 3Tamoxifen 3Cyclophosphamide 3Estrogen Receptor Modulators 2Epirubicin 2Doxorubicin 2Docetaxel 2Carboplatin 2Capecitabine 2Aromatase Inhibitors 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2pertuzumab 1ferric carboxymaltose 1atezolizumab 1Vinorelbine 1Trastuzumab 1TP protocol 1Surgical Procedures, Operative 1Radiotherapy 1Medroxyprogesterone 1Fulvestrant 1Fluorouracil 1Estrogens, Conjugated (USP) 1Cisplatin 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Ductal, Breast × Estrogen Receptor Modulators × Clear all
NCT00044291 2015-07-31

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Intarcia Therapeutics

Phase 3 Completed
865 enrolled
Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT00097344 2007-08-23

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Intarcia Therapeutics

Phase 3 Terminated
842 enrolled
Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡